Dr. Jack West hosts Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Riad Abdeljalil, Dr. Khaled Abdel Aziz, Dr. Ashraf Abdel Ghani, Dr. Ahmed Rabea, and Dr. Hussein Soudy.
As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Lizza Hendriks moderates a discussion in Dutch with Dr. Marthe Paats and Dr. Gerrina Ruiter on the treatment of EGFR non-small cell lung cancer.
Lung Cancer Considered: Targeting EGFR NSCLC by IASLC
Lung Cancer Considered in Japanese---2025 WCLC Highlights by IASLC
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Min Hee Hong. Guest Host: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Instagram: @fe0120 Guest Name(s) & Title(s): Jeongmin Seo, MD, MSc Assistant Professor, Medical Oncology Seoul National University Bundang Hospital Min Hee Hong, MD Associate Professor, Yonsei Cancer Center Severance Hospital, Seoul
IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy by IASLC
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, guest host Dr. Kuan Yu Chen moderates a discussion in Mandarin with Dr. Bin-Chi Liao and Dr. Jeng-Sen Tseng, leading lung cancer experts in Taiwan, who share their perspectives on key highlights from the conference.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Clarissa Baldotto, Dr. Lilian Faroni, Dr. Maria Cecilia Mathias, and Dr. Wiliiam William, Jr.
In this episode, recorded live in Spanish at WCLC 2025, Dr. Diego Carrillo reflects on his experiences as a junior faculty member at WCLC 2025. In conversation with host Dr. Narjust Florez, they discuss conference activities, research highlights, and how WCLC helps junior faculty build their networks and shape the future of lung cancer care and research.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Alona Zer moderates a discussion in Hebrew about highlights from the conference with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel.
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference. Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR positive previously treated NSCLC. Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about highlights from the conference with Dr. Laura Mezquita and Dr. Jorge Alatorre Alexander.
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. David Planchard discusses the data that we all were waiting for the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.
In this episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu share tips for first-time attendees of the World Conference on Lung Cancer (WCLC). Recorded live at WCLC 2025, hear their 10 key recommendations to make the most of your experience, including advice on how to sneak self-care into your busy conference schedule.
LCC in Mandarin: Neoadjuvant and Perioperative Therapy for Locally Advanced NSCLC by IASLC
LCC in Greek: Virtual Tumor Board - ALK NSCLC by IASLC
Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy by IASLC
LCC in Cantonese: Novel Treatment for Advanced EGFR Mutant Lung Cancer by IASLC
FDA Approval: Zongertinib for HER2 Mutant NSCLC by IASLC
As part of IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Asrar AlAhmadi and Dr. Maya Khalil. The group discusses the journey and career development of Arabic women in the field of thoracic oncology.
Artificial Intelligence (AI) and Lung Cancer Treatment Decisions by IASLC
Artificial Intelligence (AI) and Lung Cancer Treatment Decisions by IASLC
LCC in Romanian: Management of Unresectable, EGFR-mutated Stage III Lung Cancer in Romania by IASLC
LCC in Japanese: ASCO 2025 Highlights by IASLC
On December 5, 2025, we will kick off the IASLC ASCO 2025 North America Conference on Lung Cancer. Guest include Dr. Ramesh Rengan, the Peter Wootton Professor and Chair of Radiation Oncology at the University of Washington and Senior Vice President of the Fred Hutchinson Cancer Center and Dr. Kristen Marrone, Associate Professor of Oncology and Director of the Medical Oncology and Hematology Fellowship Program at Johns Hopkins University.
FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC by IASLC
FDA Approval: Sunvozertinib for EGFR Exon 20 by IASLC
LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC by IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Chunxia Su and Dr. Collin Blakely. The case explores resectable EGFR NSCLC.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.
ASCO 2025 Highlights Guests: Charu Aggarwal, MD, MPH Leslye M. Heisler Professor of Medicine Section Chief, Thoracic and Head & Neck Cancer Associate Director, Penn Center for Cancer Care Innovation (PC3I) University of Pennsylvania Patrick Forde, MBBCh Associate Professor Johns Hopkins University
In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.
LCC in Korean: Lung Cancer Updates & Future Directions by IASLC
Global Advances and Persistent Disparities in Lung Cancer Treatment by IASLC
Dr. Bryant Lin Teaching My Cancer by IASLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Mihaela Aldea about the key information about RET-positive NSCLC, from diagnostic challenges to treatment selection. Join us in this lively discussion.
Live from Texas Lung - Patient Education by IASLC
Guest: Dr. Corey Langer is the Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania
Virtual Tumor Board: Targeting Residual Disease by IASLC
LCC in Korean: 2024 Lung Cancer Updates by IASLC
The Microbiome and Immunotherapy for Lung Cancer by IASLC
Live from TTLC25: Brain Metastasis by IASLC
LCC in Mandarin: Virtual Tumor Board - EGFR NSCLC by IASLC
Host: Ece Cali Daylan, Assistant Professor of Medicine, Division of Oncology at Washington University School of Medicine Guest: Saadettin Kilickap Guest: Ozden Altundag